A Case of ALK-rearrangement-positive Lung Adenocarcinoma in Which the Primary Lesion and Gastric Metastasis Showed Different Responses to Alectinib

DOI Web Site 10 References Open Access
  • Ishizuka Masahiro
    Department of Respiratory Medicine, Shuuwa General Hospital Department of Respiratory Medicine, Tokyo Medical and Dental University Hospital
  • Ochi Junichi
    Department of Respiratory Medicine, Shuuwa General Hospital

Bibliographic Information

Other Title
  • アレクチニブが原発巣と胃転移巣で異なる効果を認めたALK陽性肺癌の1例

Search this article

Description

<p>Background. The guidelines recommend alectinib as the primary therapy for ALK-positive lung cancer; however, it has the same problems with resistance as crizotinib. Meanwhile, gastric metastasis of lung cancer is rare, and there have been no reports of ALK-positive gastric metastatic lesions. We encountered a case in which a patient's primary lesion and gastric metastatic lesion displayed different responses to alectinib. We herein report the case, including the histopathological assessment of the gastric metastatic lesion after alectinib treatment. Case. A 61-year-old man was diagnosed with ALK-rearrangement-positive lung adenocarcinoma (cT2aN3M1c, stage IVB). He was treated with alectinib and the primary lung lesion showed a sustained response for one year. However, the gastric metastatic lesion showed little response during the course of treatment. Gastrointestinal endoscopy performed after 8 months of treatment revealed that the gastric lesion was markedly increased in size and was bleeding continually. The patient underwent total gastrectomy the following month. Immunohistochemical staining revealed that the gastric lesion remained ALK-positive after the acquisition of resistance to alectinib. Conclusion. In this case, the primary lesion and gastric metastatic lesion showed different responses to alectinib. Because immunostaining of the gastric lesion revealed that it remained ALK-positive after the lesion had acquired resistance to alectinib, we hypothesized that the bypass of the signaling pathways might have been related to the development of resistance by the metastatic lesion. The establishment of methods for identifying resistance mechanisms and the development of appropriate therapies based on these results are expected in the future.</p>

Journal

  • Haigan

    Haigan 58 (3), 231-236, 2018-06-20

    The Japan Lung Cancer Society

References(10)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top